RT Journal Article
SR Electronic
T1 Sarilumab use in severe SARS-CoV-2 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20094144
DO 10.1101/2020.05.14.20094144
A1 Gremese, Elisa
A1 Cingolani, Antonella
A1 Bosello, Silvia Laura
A1 Alivernini, Stefano
A1 Tolusso, Barbara
A1 Perniola, Simone
A1 Landi, Francesco
A1 Pompili, Maurizio
A1 Murri, Rita
A1 Santoliquido, Angelo
A1 Garcovich, Matteo
A1 Sali, Michela
A1 Pascale, Gennaro De
A1 Gabrielli, Maurizio
A1 Biscetti, Federico
A1 Montalto, Massimo
A1 Tosoni, Alberto
A1 Gambassi, Giovanni
A1 Rapaccini, Gian Ludovico
A1 Iaconelli, Amerigo
A1 Verme, Lorenzo Zileri Del
A1 Petricca, Luca
A1 Fedele, Anna Laura
A1 Lizzio, Marco Maria
A1 Tamburrini, Enrica
A1 Natalello, Gerlando
A1 Gigante, Laura
A1 Bruno, Dario
A1 Verardi, Lucrezia
A1 Taddei, Eleonora
A1 Calabrese, Angelo
A1 Lombardi, Francesco
A1 Bernabei, Roberto
A1 Cauda, Roberto
A1 Franceschi, Francesco
A1 Landolfi, Raffaele
A1 Richeldi, Luca
A1 Sanguinetti, Maurizio
A1 Fantoni, Massimo
A1 Antonelli, Massimo
A1 Gasbarrini, Antonio
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.05.14.20094144.abstract
AB Importance Interleukin-6 signal blockade has shown preliminary beneficial effects in treating aberrant host inflammatory response against SARS-CoV-2 leading to severe respiratory distress.Objective to describe the effect of off-label intravenous use of Sarilumab in patients with severe SARS-CoV-2-related pneumonia.Design Observational clinical cohort study.Setting Fondazione Policlinico Universitario A. Gemelli IRCCS as Italian Covid reference center.Participants Patients with laboratory-confirmed SARS-CoV-2 infection and respiratory distress with PaO2/FiO2 ratio<300 treated with Sarilumab between March 23rd – April 4th, 2020. Date of final follow-up was April 18, 2020.Main outcomes and measures We describe the clinical outcomes of 53 patients with SARS-CoV-2 severe pneumonia treated with intravenous Sarilumab in terms of pulmonary function improvement or Intensive Care Unit (ICU) admission rate in medical wards setting and of live discharge rate in ICU treated patients as well as in terms of safety. Each patient received Sarilumab 400 mg administered intravenously on day 1, with eventual additional infusion based on clinical judgement, and was followed for at least 14 days, unless previously discharged or dead. No gluco-corticosteroids were used at baseline.Results Of the 53 SARS-CoV-2pos patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a second infusion). The median PaO2/FiO2 of patients in the Medical Ward was 146(IQR:120-212) while the median PaO2/FiO2 of patients in ICU was 112(IQR:100-141.5), respectively.Within the medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved (46.1% after 24 hours, 61.5% after 3 days), 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7% after Sarilumab administration: 1(2.5%) patient died in the Medical Ward whilst 2(14.2%) patients died in ICU, respectively.Conclusions and relevance IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical benefit and good safety.Question SARS-CoV-2 infection remains a disease with many unknown aspects for which there are no therapies with proven efficacy. To date, it is recognized that COVID-19 disease may lead to the development of a cytokine storm for which drugs as IL-6R inhibitors may have beneficial effect.Findings In this observational clinical study, we reported the efficacy and safety of intravenous Sarilumab use in SARS-CoV-2 severe pneumonia with a global resolution rate of 83.0% (89.7% in medical wards and 64.3% in ICU) and an overall mortality rate of 5.7%.Meaning IL-6R-inhibition is an effective approach for severe SARS-CoV-2 pneumonia and intravenous Sarilumab is a promising treatment approach leading to an important clinical benefit and good safety in the short term.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.A.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN.A.